Live price temporarily unavailable.
HUTCHMED (HCM) is a Health Care company. Latest news and coverage below.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $216.1M | $241.2M | $214.1M | $204.9M | $228.0M | $356.1M | $426.4M | $838.0M | $630.2M | $548.5M |
| Growth (year over year) | +21.3% | +11.6% | −11.2% | −4.3% | +11.3% | +56.2% | +19.7% | +96.5% | −24.8% | −13.0% |
| Gross profit | $66.9M | $71.4M | — | — | — | — | $115.3M | $453.6M | $281.3M | $212.2M |
| Gross margin | 31.0% | 29.6% | — | — | — | — | 27.0% | 54.1% | 44.6% | 38.7% |
| Operating income | −$46.7M | −$53.4M | −$92.6M | −$146.4M | −$196.7M | −$328.3M | −$407.7M | $18.4M | −$43.7M | −$39.2M |
| Operating margin | −21.6% | −22.1% | −43.3% | −71.4% | −86.3% | −92.2% | −95.6% | 2.2% | −6.9% | −7.1% |
| Net income | $11.7M | −$26.7M | −$74.8M | −$106.0M | −$125.7M | −$194.6M | −$360.8M | $100.8M | $37.7M | $456.9M |
| Net margin | 5.4% | −11.1% | −34.9% | −51.7% | −55.2% | −54.7% | −84.6% | 12.0% | 6.0% | 83.3% |
| EPS (diluted) | $0.20 | −$0.43 | −$1.13 | −$0.16 | −$0.18 | −$0.25 | −$0.43 | $0.12 | $0.04 | $0.52 |
| Balance sheet | ||||||||||
| Cash and equivalents | $79.4M | $85.3M | $86.0M | $121.2M | $235.6M | $377.5M | $313.3M | $283.6M | $154.0M | $71.3M |
| Total assets | $342.4M | $597.9M | $532.1M | $465.1M | $724.1M | $1.37B | $1.03B | $1.28B | $1.27B | $1.75B |
| Total liabilities | $138.4M | $113.0M | $119.9M | $152.2M | $205.2M | $333.1M | $392.6M | $536.4M | $502.3M | $501.8M |
| Long-term debt | $26.8M | $30.0M | $26.7M | $26.8M | $26.9M | $26.9M | $18.1M | $48.2M | $59.4M | $68.2M |
| Shareholders' equity | $184.3M | $461.7M | $389.0M | $288.0M | $484.1M | $986.9M | $610.4M | $730.5M | $759.9M | $1.24B |
| Cash flow | ||||||||||
| Operating cash flow | −$9.57M | −$8.94M | −$32.8M | −$80.9M | −$62.1M | −$204.2M | −$268.6M | $219.3M | $497.0K | −$64.7M |
| Capital expenditure | $4.33M | $5.02M | $6.36M | $8.56M | $7.95M | $16.4M | $36.7M | $32.6M | $17.9M | $14.1M |
| Free cash flow | −$13.9M | −$14.0M | −$39.2M | −$89.5M | −$70.0M | −$220.6M | −$305.3M | $186.6M | −$17.4M | −$78.8M |
| Share buybacks | $604.0K | $1.37M | $5.45M | $346.0K | $12.9M | $27.3M | $48.1M | $9.07M | $36.1M | — |
| Q1 FY18Mar 2018 | Q2 FY18†Jun 2018 | Q3 FY18†Sep 2018 | Q4 FY18†Dec 2018 | Q1 FY19Mar 2019 | Q2 FY19†Jun 2019 | Q3 FY19†Sep 2019 | Q4 FY19†Dec 2019 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $52.3M | $49.9M | $58.8M | $53.1M | $52.2M | $50.0M | $49.3M | $53.3M |
| Growth (year over year) | — | — | — | — | −0.3% | +0.4% | −16.1% | +0.4% |
| Operating income | −$25.0M | −$28.7M | −$14.8M | −$24.2M | −$36.0M | −$36.0M | −$35.9M | −$38.4M |
| Operating margin | −47.8% | −57.5% | −25.1% | −45.5% | −69.1% | −71.9% | −72.8% | −72.0% |
| Net income | −$11.7M | −$21.0M | −$25.6M | −$16.5M | −$19.9M | −$25.5M | −$31.1M | −$29.6M |
| Net margin | −22.4% | −42.0% | −43.5% | −31.1% | −38.1% | −50.9% | −63.0% | −55.4% |
| EPS (diluted) | −$0.02 | −$0.47 | $0.40 | −$1.04 | −$0.03 | −$0.04 | −$0.04 | −$0.05 |
| Balance sheet | ||||||||
| Cash and equivalents | $78.1M | $75.3M | $115.6M | $86.0M | $91.7M | $83.4M | $97.1M | $121.2M |
| Total assets | — | $577.9M | — | $532.1M | $539.3M | $495.2M | $454.1M | $465.1M |
| Total liabilities | — | $120.1M | — | $119.9M | $138.9M | $122.2M | $116.3M | $152.2M |
| Long-term debt | — | $26.7M | — | $26.7M | $26.8M | $0 | $0 | $26.8M |
| Shareholders' equity | $478.4M | $431.7M | $424.7M | $389.0M | $375.8M | $347.9M | $313.5M | $288.0M |
| Cash flow | ||||||||
| Operating cash flow | −$30.8M | $12.2M | −$315.0K | −$13.9M | −$28.9M | −$1.12M | −$33.5M | −$17.4M |
| Capital expenditure | $1.32M | $761.0K | $1.35M | $2.93M | $1.36M | $2.49M | $1.77M | $2.95M |
| Free cash flow | −$32.2M | $11.5M | −$1.67M | −$16.9M | −$30.3M | −$3.61M | −$35.2M | −$20.3M |
| Share buybacks | $5.45M | $0 | $0 | $0 | $346.0K | $0 | $0 | $0 |
From HUTCHMED's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning HUTCHMED in our feed yet.